Systematic review of pharmacological treatments for depressive symptoms in Huntington's disease

Movement Disorders

Volumn 29, Issue 12, 2014, Pages 1556-1561

  Moulton, Calum D ^a   Hopkins, C W P ^b   Bevan Jones, W Richard ^c  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b BERKSHIRE HEALTHCARE NHS FOUNDATION TRUST   (United Kingdom)

^c CAMBRIDGE UNIVERSITY HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

Antidepressant; Depression; Rating scale; Suicidality; Systematic review

Indexed keywords

ANTIDEPRESSANT AGENT; ATOMOXETINE; CITALOPRAM; FLUOXETINE; LITHIUM; MODAFINIL; MOOD STABILIZER; NEUROLEPTIC AGENT; VENLAFAXINE;

ARTICLE; DEPRESSION; HUMAN; HUNTINGTON CHOREA; MEDLINE; META ANALYSIS (TOPIC); OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PSYCINFO; RETROSPECTIVE STUDY; SYSTEMATIC REVIEW; WEB OF SCIENCE; COMPLICATION;

ANTIDEPRESSIVE AGENTS; DEPRESSION; HUMANS; HUNTINGTON DISEASE;

EID: 84927518627     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.25980     Document Type: Article

References (21)

1. The Huntington's Disease Collaborative Research Group. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. Cell 1993;72:971-983.
2. Rosenblatt A, Leroi L. Neuropsychiatry of Huntingon's disease and other basal ganglia disorders. Psychosomatics 2000;41:24-30.
3. Ho AK, Gilbert AS, Mason SL, Goodman AO, Barker RA. Health-related quality of life in Huntington's disease: which factors matter most? Mov Disord 2009;24:574-578.
4. Hubers AA, van Duijn E, Roos RA, et al. Suicidal ideation in a European Huntington's disease population. J Affect Disord 2013;151:248-258.
5. Mestre T, Ferreira J, Coelho MM, Rosa M, Sampaio C. Therapeutic interventions for symptomatic treatment in Huntington's disease. Cochrane Database Syst Rev 2009;3:CD006456.
6. van Duijn E, Reedeker N, Giltay EJ, Eindhoven D, Roos RA, van der Mast RC. Course of irritability, depression and apathy in Huntington's disease in relation to motor symptoms during a two-year follow-up period. Neurodeg Dis 2014;13:9-16.
7. Beglinger LJ, Adams WH, Langbehn D, et al. Results of the citalopram to enhance cognition in Huntington disease trial. Mov Disord 2014;29:401-405.
8. th ed, Wiley-Blackwell, 2012.
9. Holl AK, Wilkinson L, Painold A, Holl EM, Bonelli RM. Combating depression in Huntington's disease: effective antidepressive treatment with venlafaxine XR. Int Clin Psychopharmacol 2010;25:46-50.
10. Cipriani A, Furukawa TA, Salanti G, et al. Comparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments meta-analysis. Lancet 2009;373:746-758.
11. Como PG, Rubin AJ, O'Brien CF, et al. A controlled trial of fluoxetine in nondepressed patients with Huntington's disease. Mov Disord 1997;12:397-401.
12. Beglinger LJ, Adams WH, Paulson H, et al. Randomized controlled trial of atomoxetine for cognitive dysfunction in early Huntington disease. J Clin Psychopharmacol 2009;29(5): 484-7.
13. Duff K, Beglinger LJ, O'Rourke ME, Nopoulos P, Paulson HL, Paulsen JS. Risperidone and the treatment of psychiatric, motor, and cognitive symptoms in Huntington's disease. Ann Clin Psychiatry 2008;20:1-3.
14. Brusa L, Orlacchio A, Moschella V, Iani C, Bernardi G, Mercuri NB. Treatment of the symptoms of Huntington's disease: preliminary results comparing aripiprazole and tetrabenazine. Mov Disord 2009;24:126-129.
15. Ciammola A, Sassone J, Colciago C, et al. Aripiprazole in the treatment of Huntington's disease: a case series. Neuropsychiatr Dis Treat 2009;5:1-4.
16. Paleacu D, Anca M, Giladi N. Olanzapine in Huntington's disease. Acta Neurol Scand 2002;105:441-444.
17. Squitieri F, Cannella M, Porcellini A, Brusa L, Simonelli M, Ruggieri S. Short-term effects of olanzapine in Huntington disease. Neuropsychiatry Neuropsychol Behav Neurol 2001;14:69-72.
18. Cao L. Lithium treatment in patients with Huntington disease and suicidal behaviour. J Clin Psychopharmacol 2013;33:819-821.
19. Blackwell AD, Paterson NS, Barker RA, Robbins TW, Sahakian BJ. The effects of modafinil on mood and cognition in Huntington's disease. Psychopharmacology (Berl.) 2008;199:29-36.
20. Walsh BT, Seidman SN, Sysko R, Gould M. Placebo response in studies of major depression: : variable, substantial, and growing. JAMA 2002;287:1840-1847.
21. National Institute for Health and Care Excellence. Depression: the treatment and management of depression in adults (update), 2009.